Company News
Zydus Gets DCGI Nod for Anti-Malarial Phase III Trials
Zydus Lifesciences received DCGI approval to initiate two Phase III clinical trials for its novel anti-malarial drug candidate, Zintrodiazine.
The trials will enroll 1,041 patients total to evaluate e
